Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings LK, Hsia S, Bays H, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
Breaking news
Social determinants of health and cancer prevention guideline behaviors
Chiang KE, Padilla HM, Callands TA, et al.
JAMA Netw Open. Pub. online 3 Nov 2025.
Leggi
Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes
Gitelman SE, Simmons K, Sherr JL, et al.
Diabetologia. Pub. online 6 Nov 2025.
Leggi
Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes
Henney AE, Heague M, Riley DR, et al.
Diabetes Obes Metab. Pub. online 3 Nov 2025.
Leggi
Role of circadian health in cardiometabolic health and disease risk: a scientific statement from the American Heart Association
Knutson KL, Dixon DD, Grandner MA, et al.
Circulation. Pub. online 28 Oct 2025.
Leggi
Systematic review and meta-analysis corrected for history of smoking tobacco identifies type 1 diabetes as a possible risk factor for bladder cancer
Bennett HO, Bogumil D, Kysh L, et al.
Diabetes Res Clin Pract. 2025:112976.
Leggi
Screening natriuretic peptide levels predicts heart failure and death in individuals with type 1 and type 2 diabetes without known heart failure
Pop-Busui R, Repetto E, Baron J, et al.
Diabetes Care. Pub. online 30 Oct 2025.
Leggi
EMA partners with content creators to promote safe and responsible use of GLP-1 medicines
21 ottobre 2025
Leggi
Pharmacological therapies for type 2 diabetes: future approaches
Bailey CJ
Diabetologia. Pub. online 31 Oct 2025.
Leggi
Effects of modern glucose monitoring and insulin delivery technologies on patient-reported outcomes and experiences in individuals with type 1 diabetes: a systematic review and meta-analysis
Gao M, Saravanan S, Munyombwe T, et al.
Diabetes Care. Pub. online 30 Oct 2025.
Leggi